Then, we analyzed the co-expression of LRP2 mutations with immune receptors, immunostimulators, MHC molecules, and chemokines in BLCA, COAD, LUAD, LUSC, SKCM, STAD, UCEC, and UCS, because they have a high percentage of LRP2 mutations (Fig. S4B). The gene discussed is HLA-C; the disease is bladder transitional cell carcinoma.